ASH 2018: Very exciting new data from the MURANO-study about treatment of relapsed/Refractory CLL

BestPractice | des 2018 | |

In this MEDtalk John Gribben, Professor, MD DSc, Barts Cancer Institute, University of London, present the key data from MURANO study about treatment of relapsed/Refractory CLL.